<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21724">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942512</url>
  </required_header>
  <id_info>
    <org_study_id>PN12145</org_study_id>
    <nct_id>NCT01942512</nct_id>
  </id_info>
  <brief_title>Risk Factors for Intracranial Aneurysm Recanalization After Endovascular Treatment.</brief_title>
  <acronym>ARETA</acronym>
  <official_title>Evaluation of Risk Factors Associated With Intracranial Aneurysm Recanalization After Endovascular Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endovascular treatment is now the first line treatment for the management of intracranial
      aneurysms. However aneurysm recanalization is an important limitation to this treatment.
      Several factors seems to be associated with aneurysm recanalization including medical
      history of the patient, aneurysm status (ruptured or unruptured), aneurysm size and
      location, modalities of treatment, immediate post-operative occlusion of the aneurysm.

      A precise knowledge of factors increasing the risk of aneurysm recanalization is quite
      important to optimize strategy of treatment and reduce the recanalization rate. No large,
      prospective, multicenter trial dealing with this question has been published in the
      literature.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of intracranial aneurysms is high (between 2 and 3%). The major risk of an
      intracranial aneurysm is its rupture leading to intracranial bleeding (subarachnoid,
      parenchymal and/or intraventricular) associated with mortality and morbidity.

      Endovascular treatment is now the first line treatment for both ruptured and unruptured
      aneurysms. One major limitation of this treatment is aneurysm recanalization observed in
      approximately 20% of aneurysms and leading to retreatment in approximately 10% of aneurysms.

      CARAT trial has shown that the risk of rebleeding after aneurysm coiling is significantly
      associated with the quality of aneurysm occlusion. The risk of rebleeding is 1.1% in case of
      complete occlusion, 2.9% when aneurysm occlusion is between 91 and 99%, 5.9% when aneurysm
      occlusion is between 70 et 90%, and 17.6% when aneurysm occlusion is less than 70%. However
      it should be outlined that few studies have clearly analyzed the relation between
      recanalization and rebleeding.

      Several factors are probably associated with aneurysm recanalization. Ruptured aneurysms are
      more prone to aneurysm recanalization than unruptured aneurysm. Age, elevated blood
      pressure, smoking probably play a role in aneurysm recanalization. Anatomical features are
      also probably key factors for aneurysm recanalization. Aneurysm and neck sizes are probably
      important factors for aneurysm recanalization. The role of aneurysm location is more
      controversial. Therapeutic factors certainly play also an important role, but precise
      analyses are still missing. The quality of post-operative aneurysm occlusion is probably
      important for the future evolution of the aneurysm. Surface-modified coils have not
      demonstrated any efficacy to prevent aneurysm recanalization. The role of adjunctive
      techniques has also not precisely be evaluated (remodeling, stenting).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>aneurysm recanalization</measure>
    <time_frame>assessed at 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1275</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>ARETA</arm_group_label>
    <description>All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular treatment of intracranial aneurysm</intervention_name>
    <arm_group_label>ARETA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular
        treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated by endovascular approach for intracranial aneurysm(s)

          -  Patients older than 18 years

          -  Patients accepting to participate to the study

        Exclusion Criteria:

          -  Patients younger than 18 years

          -  Patients protected by law

          -  Patients already treated by endovascular approach for an intracranial aneurysm

          -  Patients having a brain arteriovenous malformation

          -  Patients having a fusiform aneurysm

          -  Patients having a dissecting aneurysm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurent PIEROT, PhD, MD</last_name>
    <phone>326788734</phone>
    <phone_ext>33</phone_ext>
    <email>lpierot@chu-reims.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gwendoline ARNOULT</last_name>
    <phone>3326789267</phone>
    <phone_ext>33</phone_ext>
    <email>garnoult@chu-reims.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xavier BARREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrick COURTHEOUX, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Beatrix JEAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent SPELLE, Ph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sophie GALLAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frédéric RICOLFI, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erwah KALSOUM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francis TURJMAN, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de MONTPELLIER</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alain BONAFE, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Serge BRACARD, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hubert DESAL, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jacques SEDAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Denis TRYSTRAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent PIEROT, PhD, MD</last_name>
      <phone>3326788764</phone>
      <phone_ext>33</phone_ext>
      <email>lpierot@chu-reims.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gwendoline ARNOULT</last_name>
      <phone>3326789267</phone>
      <phone_ext>33</phone_ext>
      <email>garnoult@chu-reims.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent PIEROT, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Yves GAUVRIT, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mohammed AGGOUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Georges RODESCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christophe COGNARD, Ph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Denis HERBRETEAU, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 11, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracranial Aneurysm - Endovascular treatment -</keyword>
  <keyword>Coiling - Stenting - Flow diversion - Flow disruption -</keyword>
  <keyword>Recanalization - Risk factors</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
